Metabolic disorders and gut microbiota by Kotrova, Anna D. et al.
© St. Petersburg State University, 2020
Вестник СПбГУ. Медицина. 2020. Т. 15. Вып. 3
https://doi.org/10.21638/spbu11.2020.302 177
UDC 579.6+616.008
Metabolic disorders and gut microbiota*
A. D. Kotrova, A. N. Shishkin, M. V. Lukashenko
St. Petersburg State University,  
7–9, Universitetskaya nab., St. Petersburg, 199034 Russian Federation
For citation: Kotrova A. D., Shishkin A. N., Lukashenko M. V. Metabolic disorders and gut microbiota. 
Vestnik of Saint Petersburg University. Medicine, 2020, vol. 15, issue 3, pp. 177–183.
https://doi.org/10.21638/spbu11.2020.302
Obesity, type 2  diabetes mellitus, metabolic syndrome are metabolic widespread disorders 
that arise both under the influence of external factors (physical inactivity, high-calorie diet) 
and under the influence of internal factors. The latter includes the intestinal microbiota which 
deserves more and more attention in developing new strategies for the correction of metabolic 
diseases. The discovery of new approaches for the gut microbiota study (metagenomic, me-
tabolomic) gives a new insight into the diversity and involvement of intestinal bacteria in the 
metabolic processes of the whole organism. This article are reviewed the mechanisms of the 
gut bacteria impact on lipid and carbohydrate metabolism, the relationship of bacteria species 
and their metabolites with tissue insulin sensitivity, body mass index. Special attention in the 
regulation of tissue insulin sensitivity is paid to the role of short-chain fatty acids and second-
ary bile acids, which are metabolites of gut bacteria. Understanding the influence of human 
microbiota and its metabolites on lipid and carbohydrate metabolism provides the basis for 
the development of new approaches to the prevention and treatment of socially significant 
metabolic diseases such as type 2 diabetes mellitus, obesity, metabolic syndrome.
Keywords: microbiota, metabolic disorders, lipopolysaccharide, short-chain fatty acids, bile 
acids.
Introduction
Metabolic diseases have been a global problem for the last century all over the world. 
Thus, the prevalence of obesity in some developed countries reaches pandemic levels, and 
for type 2 diabetes mellitus (DM), there is a progressive incidence increase annually.
Metabolic syndrome (MS) is presented in a quarter of the adult population in the 
world and has become a serious public health problem every year, especially in urban ar-
eas. In addition to genetic predisposition, there are such important external factors as low 
physical activity and high-calorie diet, which contribute to the development of metabolic 
disorders [1].
In recent years, many omics technologies studies have been conducted, the results 
of which indicate a possible link between qualitative and quantitative changes in the gut 
microbiota composition and the development of obesity, DM, MS [2].
The gut microbiota, with its vast and unique genome, profoundly influence on human 
metabolism. First, it helps in metabolic pathways functioning by the synthesis of essential 
vitamins (especially group B); secondly, gut bacteria, through the fermentation of indi-
* The reported study was funded by RFBR, project number 20-315-90106.
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gestible carbohydrates, provide the human organism with short-chain fatty acids (SCFA), 
which are either a source of energy, or act as signaling molecules by binding to membrane 
receptors for the integration of metabolic functions [3].
European-style diets rich in saturated fats, simple carbohydrates and devoid of dietary 
fiber is considered as altering the structure of the gut microbiota factor, which adversely 
affects gut permeability and colonization by metabolic disorders-causing gut bacteria. 
In this article are reviewed the mechanisms of the gut bacteria influence on the hu-
man metabolism, the links of bacteria and their metabolites with body mass index, insulin 
sensitivity and lipid metabolism. Understanding these processes and correlations provides 
the basis for the development of new approaches to the prevention and treatment of so-
cially significant metabolic diseases such as DM, obesity, MS.
Microbiota and its composition
Microbiota is a term used to characterize the microbiocenosis of organ systems. So, 
the gastrointestinal tract is the largest habitat of bacteria and includes more than 50 genera 
and more than 500 species of microorganisms, the number of which gradually increases 
along the intestine, reaching a maximum value in the colon, which is approximately 109–
1011 CFU/ml [4–7]. This gradient is mainly due to the rapid luminal flow, low pH in the up-
per gastrointestinal tract, and the secretion of antibacterial substances such as bile acids [8].
The main gut microbiota bacterial types are Firmicutes, Bacteroidetes, Actinobac-
teria, Proteobacteria, Verrucomicrobia, Fusobacteria, and Euryarchaeota (Table) [2; 9]. 
Phylums Firmicutes and Bacteroidetes characterized by the highest species diversity and 
account for 90 % of the total gut bacteria number [10]. The species diversity of bacteria 
varies in different parts of the intestine [11; 12]. Thus, in the small intestine is dominated 
Firmicutes (Lactobacillaceae) and Proteobacteria (Enterobacteriaceae), and in the co-
lon — Bacteroidetes (Bacteroidaceae, Prevotellaceae, Rikenellaceae), Firmicutes (Lachno-
spiraceae, Ruminococcaceae) and only representative Verrucomicrobia — Akkermansia 
muciniphila [13].
Table. Bacteria in the human gut microbiota [2; 10; 15]
Phylum Gram-stain Genus or species
Bacteroidetes Gram (–) Bacteroides, Parabacteroides, Prevotella, Porphyromonas, Odoribacter, 
Barnesiella, Alistipes 
Firmicutes Gram (+) Lactobacillus, Ruminococcus, Mycoplasma, Enterococcus, 
Streptococcus, Staphylococcus, Clostridium cocleatum, Roseburia, 
Oscillibacter spp., Intestinibacter spp., Faecalibacterium prausnitzii, 
Blautia, Dorea, Coprococcus
Proteobacteria Gram (–) Esсherichia сoli, Esсherichia spp., Proteus, Pseudomonas
Actinobacteria Gram (+) Bifdobacteria spp.
Verrucomicrobia Gram (–) Akkermansia muciniphila
The functions of the intestinal microbiota are numerous and varied: these are protec-
tive (colonization resistance), regulation of the immune, endocrine and nervous systems, 
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metabolism of nutrients and xenobiotics, synthesis of vitamins (folates, vitamin K, biotin, 
riboflavin (B2), cobalamin (B12)), bile acids, biologically active compounds and detoxica-
tion [11]. These processes play an essential role in the metabolism of the human host. The 
development of new methods for studying the intestinal microbiota (RT-PCR, omics tech-
nologies) gave the new insight into the diversity and impact of gut bacteria to the meta-
bolic processes of the whole organism. In this regard, in the last decade, the gut microbiota 
has received more and more attention as a new factor involved in the pathophysiology of 
metabolic diseases [14; 15].
Mechanisms of gut microbiota influence 
on metabolic processes in the human body
The most important factor determining the composition and metabolism of the 
gut microbiota in the modern world is diet and food additives [16]. In a 2015 Ameri-
can study, it was shown that emulsifiers (carboxymethylcellulose, polysorbate-80), widely 
used in food, caused nonspecific inflammation, obesity and MS in normal mice. These 
compounds altered the gut microbial composition and increased its pro-inflammatory 
potential. Transplantation of fecal microbiota processed with an emulsifier to gnotobiont 
mice led to the phenotype of obese mice, which confirms the impact of these additives to 
the development of metabolic disorders [17].
Consumption of a high-fat diet leads to disruption of the gut microbiota composition 
by inducing the death of gram-negative bacteria (mainly Bacteroidetes and Proteobacteria), 
thus promoting the release of large amounts of lipopolysaccharide (LPS), which is an inte-
gral part of their cell wall [18]. In case of the intestinal barrier violation, the permeability of 
the mucous membrane increases, and LPS from the large intestine is transported in greater 
quantities into the bloodstream through the intercellular spaces in the intestinal wall. LPS 
mediates the formation of the CD-14  complex with Toll-like receptor-4  of macrophages 
and endothelial cells, which causes the release of pro-inflammatory cytokines: interleukin-1 
(IL-1), interleukin-6 (IL-6), TNF-α [2; 19; 20]. The above changes lead to the development 
of systemic low-grade inflammation and, as a consequence, a decrease in insulin sensitivity, 
increased lipogenesis in the liver, and activation of inflammation in adipose tissue [19].
In addition to the influence of external factors, several mechanisms of gut microbiota 
influence on the metabolism of the human host have been studied. When polysaccharides 
are broken down with the participation of microbiota to easily assimilated monosaccha-
rides, either they are absorbed by enterocytes, or they are fermented by the microbiota 
with the formation of short-chain fatty acids (SCFA) — acetic, propionic, butyric acids. 
Subsequently, SCFAs are delivered through the portal vein system to the liver, where they 
serve as substrates for gluconeogenesis and de novo lipogenesis. According to A. A. Kur-
mangulov study, obese people have the decrease number of SCFAs, and the absolute level 
of all SCFAs had an inverse moderate correlation with the BMI value. Considering that the 
main producers of SCFA in the gut are obligate firmicutes anaerobes, it can be assumed 
that with an increase in BMI, there is a decrease in the metabolic activity of lactic acid mi-
croorganisms, mainly bifidobacteria and lactobacilli. Thus, the lowest values of the SCFA 
are determined in the group with 3rd degree obesity [21].
SCFAs are ligands for G-protein-coupled receptors (GPCRs) such as GPR41, 
GPR43 and GPR109A, which are expressed in intestinal neuroendocrine cells. These spe-
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cialized cells perform important endocrine functions in the intestines and pancreas. In the 
production of SCFA, GPCR stimulate the tyrosine-tyrosine peptide (YY-peptide), which 
slows down intestinal motility and thus facilitates the absorption of nutrients [19; 22; 23]. 
Thus, in patients receiving propionic acid therapy for 24 weeks, an increase in the produc-
tion of glucagon-like peptide 1 (GLP-1) and YY-peptide was observed , which reduced 
appetite, increased tissue insulin sensitivity, and reduced fat deposition [23].
In a study by Perry R. J., Peng L. et al., increased acetate production by altered gut 
microbiota in high-fat rodents leads to increased ghrelin secretion and glucose-stimulated 
insulin secretion. As a result, a positive feedback loop is created, which leads to hyperpha-
gia, hypertriglyceridemia, ectopic lipid deposition in the liver and skeletal muscles, and 
insulin resistance in the liver and muscles [24]. 
Altered gut microbiota is also capable of suppressing the fasting-induced adipose fac-
tor expression (FIAF, or angiopoietin-like protein — 4) in enterocytes. FIAF is a potent 
inhibitor of lipoprotein lipase in adipose tissue. As a result, the breakdown of triacylg-
lycerol-containing lipoproteins into free fatty acids and the subsequent deposition of tri-
glycerides in adipose tissue is activated. In addition, gut microbiota inhibits the release 
of adenosine monophosphate, an activated protein kinase (AMPK), expressed mainly in 
skeletal muscle, brain and liver in response to metabolic stress (hypoxia, physical activ-
ity). This leads, on the one hand, to inhibition of mitochondrial fatty acid oxidation, ke-
togenesis, glucose uptake and insulin secretion, and, on the other hand, to an increase in 
lipogenesis, cholesterol and triglyceride synthesis [20; 25].
The intestinal microbiota is also involved in the metabolism of bile acids (FA), the 
violation of which is associated with changes in lipid metabolism and the development 
of metabolic diseases. With dysbiosis, the formation of secondary FAs and the beneficial 
effects caused by them decrease. Secondary FAs activate the secretion of GLP-1 through 
membrane FA receptors (TGR-5 receptors), which leads to an increase in glucose toler-
ance, an increase in energy consumption by brown adipose tissue and skeletal muscle 
[2]. In addition, secondary FAs formed as a result of dehydroxylation of primary FAs by 
normal microbiota (for example, Clostridium scindens) have antimicrobial effect, form-
ing colonization resistance, which prevents colonization of the intestine by pathogenic 
microorganisms [26].
The above data undoubtedly indicates that gut microbiota can play an important 
role in the prevention or development of metabolic disorders. But for this, it is neces-
sary to confirm that patients with metabolic diseases have dysbiosis, i.  e. qualitative 
and quantitative changes of microbiota composition, which determine a wide range of 
metabolic disorders, and which would show that there are changes in the gut microbiota 
ecology that cause the development of obesity and associated disorders, and not vice 
versa [20].
Early studies in this area indicated an increased Firmicutes/Bacteroidetes ratio in 
obese individuals. However, in subsequent studies using shotgun sequencing, no signifi-
cant difference was found [2; 3; 25]. In other studies, an increase in the number of Act-
inobacteria associated with obesity with a decrease in the number of Bacteroidetes and a 
constant number of Firmicutes was obtained [27]. Studies using metagenomics methods 
have found that obesity is associated with a decrease in the number of bacterial genes or 
the bacteria diversity [3]. Thus, there is currently no consensus on changes in the compo-
sition of gut microbiota in obesity [5].
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According Santos  — Marcos J. A. in patients with MS, bacteria with saccharolytic 
activity Bacteroides fragilis group, Parabacteroides distasonis, Bacteroides thetaiotaomi-
cron and Ruminococcus flavefaciens subgroup are reduced. This leads to a decrease in 
the production of SCFA (propionate and acetate), which entails a decrease in beneficial 
bacteria such as Faecalibacterium prausnitzii , Eubacterium rectale, and Fusobacterium 
nucleatum [28]. 
According to Liu R. et al., In obese individuals, the number of Bacteroides thetaio-
taomicron, which ferments glutamate, is significantly reduced , and its concentration in 
serum is increased [29]. There is also a decrease in the number of Oscillospira, Chris-
tensenellacea, Rikenellaceae, the genus Bifidobacterium and mucin-degrading bacteria 
Akkermansia muciniphila (type Verrucomicrobia). Akkermansia muciniphila has an in-
versely proportional link with the body mass index and the level of triglycerides in the 
blood plasma [3; 7].
In in vitro and in vivo studies, butyrate-producing bacteria such as Eubacterium, Fu-
sobacterium, Anaerostipes, Roseburia, Subdoligranulum and Faecalibacterium have been 
observed to have anti-inflammatory potential to reduce bacterial translocation, improve 
tight junction function, and stimulate mucin secretion for intestinal wall [30]. 
It was also recently confirmed that some species of the genus Lactobacillus may be as-
sociated with obesity [28]. Thus, Lactobacillus ingluviei and Lactobacillus acidophilus are 
associated with weight gain, while Lactobacillus casei/paracasei, Lactobacillus plantarum 
and Lactobacillus gasseri with its decline [2]. 
In patients with DM was observed low levels of bifidobacteria and butyrate-produc-
ing bacteria, in particular Faecalibacterium prausnitzii, genus Roseburia negatively cor-
related with BMI, fasting hyperglycemia, cholesterol, TG [28; 31; 32].
One large Mexican study (1065 people) found an increase in Prevotella copri, Ru-
minococcus callidus, Prevotella stercorea and a decrease in Bacteroides in MS patients. 
At the same time, in gut microbiota of people with normal weight prevailed Bacteroides 
uniformis, Vellionella parvula, Bacteroides fragilis, Bacteroides ovatus, Bacteroides acidi-
faciens, Alistipes massilensis, Roseburia faecis, E. coli [1]. 
In persons with MS, an increase of total bacterial mass was revealed due to the growth 
of opportunistic bacteria, primarily Eubacteriumlentum, Clostridium hystolyticum and 
propionicum, Nocardia, Bacilluscereus, Prevotella, fam. Enterobacteriaceae against the 
decrease in the amount of beneficial ones [33].
Conclusion
The intestinal microbiota, its genetic material and metabolites are an important part 
of the human metabolism. The transformation of organic compounds supplied with food, 
the degree of their assimilation and the effect on human organs and tissues partly depend 
on the qualitative and quantitative composition of the gut microbiota. Studies on animals 
have shown the mechanisms of the gut microbiota effect on BMI, lipid and carbohydrate 
metabolism. In large people studies, certain correlations of types, genera, species of bacte-
ria with signs of MS have been shown, however, the data are rather diverse and contradic-
tory. Further study of the bacteria genome and metabolome, link confirmation of already 
known bacteria with the development of obesity, DM, MS will allow developing new ap-
proaches to the prevention and treatment of metabolic diseases.
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